Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says
News
Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo alone, ... Read more